Pathos AI raised $237 million in a Series E round at a $3 billion valuation, led by Bristol Myers Squibb, positioning the company’s Foundry agent system as a decision engine for clinical and trial strategy. The platform uses thousands of AI agents to estimate probability of success and to guide which clinical assets to pursue, including population selection and trial design choices. Pathos also signaled an expansion beyond oncology by adding neurological datasets, with reported use of Tempus AI and a partnership with BMS focused first on Alzheimer’s-related efforts. For the biotech market, the financing underscores continued investor appetite for AI-native discovery firms, particularly those that can point to repeatable execution loops rather than only model development. The immediate question becomes how Foundry’s success-probability outputs translate into measurable clinical development progress and whether the model can sustain performance across disease areas with differing biology, endpoints, and regulatory evidence standards.